These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23532891)

  • 1. Serial diffusion MRI to monitor and model treatment response of the targeted nanotherapy CRLX101.
    Ng TS; Wert D; Sohi H; Procissi D; Colcher D; Raubitschek AA; Jacobs RE
    Clin Cancer Res; 2013 May; 19(9):2518-27. PubMed ID: 23532891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle.
    Eliasof S; Lazarus D; Peters CG; Case RI; Cole RO; Hwang J; Schluep T; Chao J; Lin J; Yen Y; Han H; Wiley DT; Zuckerman JE; Davis ME
    Proc Natl Acad Sci U S A; 2013 Sep; 110(37):15127-32. PubMed ID: 23980155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis.
    Lin CJ; Lin YL; Luh F; Yen Y; Chen RM
    Oncotarget; 2016 Jul; 7(27):42408-42421. PubMed ID: 27285755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer.
    Conley SJ; Baker TL; Burnett JP; Theisen RL; Lazarus D; Peters CG; Clouthier SG; Eliasof S; Wicha MS
    Breast Cancer Res Treat; 2015 Apr; 150(3):559-67. PubMed ID: 25833208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing.
    Clark AJ; Wiley DT; Zuckerman JE; Webster P; Chao J; Lin J; Yen Y; Davis ME
    Proc Natl Acad Sci U S A; 2016 Apr; 113(14):3850-4. PubMed ID: 27001839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101.
    Svenson S; Wolfgang M; Hwang J; Ryan J; Eliasof S
    J Control Release; 2011 Jul; 153(1):49-55. PubMed ID: 21406204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravoxel incoherent motion diffusion-weighted imaging for monitoring chemotherapeutic efficacy in gastric cancer.
    Song XL; Kang HK; Jeong GW; Ahn KY; Jeong YY; Kang YJ; Cho HJ; Moon CM
    World J Gastroenterol; 2016 Jun; 22(24):5520-31. PubMed ID: 27350730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer.
    Pham E; Birrer MJ; Eliasof S; Garmey EG; Lazarus D; Lee CR; Man S; Matulonis UA; Peters CG; Xu P; Krasner C; Kerbel RS
    Clin Cancer Res; 2015 Feb; 21(4):808-18. PubMed ID: 25524310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRLX101, a Nanoparticle-Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α.
    Tian X; Nguyen M; Foote HP; Caster JM; Roche KC; Peters CG; Wu P; Jayaraman L; Garmey EG; Tepper JE; Eliasof S; Wang AZ
    Cancer Res; 2017 Jan; 77(1):112-122. PubMed ID: 27784746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffusion-weighted MRI for imaging cell death after cytotoxic or apoptosis-inducing therapy.
    Papaevangelou E; Almeida GS; Jamin Y; Robinson SP; deSouza NM
    Br J Cancer; 2015 Apr; 112(9):1471-9. PubMed ID: 25880014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody.
    Kim H; Morgan DE; Zeng H; Grizzle WE; Warram JM; Stockard CR; Wang D; Zinn KR
    Radiology; 2008 Sep; 248(3):844-51. PubMed ID: 18710978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer.
    Gaur S; Chen L; Yen T; Wang Y; Zhou B; Davis M; Yen Y
    Nanomedicine; 2012 Jul; 8(5):721-30. PubMed ID: 22033079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antitumor and antimetastatic effects of N-trimethyl chitosan-encapsulated camptothecin on ovarian cancer with minimal side effects.
    Zhou L; Du L; Chen X; Li X; Li Z; Wen Y; Li Z; He X; Wei Y; Zhao X; Qian Z
    Oncol Rep; 2010 Oct; 24(4):941-8. PubMed ID: 20811674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models.
    Numbenjapon T; Wang J; Colcher D; Schluep T; Davis ME; Duringer J; Kretzner L; Yen Y; Forman SJ; Raubitschek A
    Clin Cancer Res; 2009 Jul; 15(13):4365-73. PubMed ID: 19549776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer.
    Pham E; Yin M; Peters CG; Lee CR; Brown D; Xu P; Man S; Jayaraman L; Rohde E; Chow A; Lazarus D; Eliasof S; Foster FS; Kerbel RS
    Cancer Res; 2016 Aug; 76(15):4493-503. PubMed ID: 27325647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer.
    Gaur S; Wang Y; Kretzner L; Chen L; Yen T; Wu X; Yuan YC; Davis M; Yen Y
    Nanomedicine; 2014 Oct; 10(7):1477-86. PubMed ID: 24768630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted tumor theranostics using folate-conjugated and camptothecin-loaded acoustic nanodroplets in a mouse xenograft model.
    Chen WT; Kang ST; Lin JL; Wang CH; Chen RC; Yeh CK
    Biomaterials; 2015; 53():699-708. PubMed ID: 25890765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Detection of Treatment-Induced Mitotic Arrest Using Temporal Diffusion Magnetic Resonance Spectroscopy.
    Jiang X; Li H; Zhao P; Xie J; Khabele D; Xu J; Gore JC
    Neoplasia; 2016 Jun; 18(6):387-97. PubMed ID: 27292027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy response evaluation in a mouse model of gastric cancer using intravoxel incoherent motion diffusion-weighted MRI and histopathology.
    Cheng J; Wang Y; Zhang CF; Wang H; Wu WZ; Pan F; Hong N; Deng J
    World J Gastroenterol; 2017 Mar; 23(11):1990-2001. PubMed ID: 28373765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring chemotherapeutic response by hyperpolarized 13C-fumarate MRS and diffusion MRI.
    Mignion L; Dutta P; Martinez GV; Foroutan P; Gillies RJ; Jordan BF
    Cancer Res; 2014 Feb; 74(3):686-94. PubMed ID: 24285723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.